Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database

Fig. 2

(a) Anchor drug classes and (b) backbones prescribed in first ART regimen (n = 1694). ART: antiretroviral therapy, NNRTI: non-nucleoside reverse transcriptase inhibitor, PI: protease inhibitor, INSTI: integrase strand transfer inhibitor, ABC: abacavir, TDF: tenofovir disoproxil fumarate, 3TC: lamivudine, FTC: emtricitabine. The years of launch of the anchor drugs by class are as follows: NNRTI: etravirine (launched in 2009) and rilpivirine (2012); PI: darunavir (2013); and INSTI: raltegravir (2008), dolutegravir (DTG) (2014), DTG/ABC/3TC (2015) and elvitegravir/cobi/TDF/FTC (2013). One patient prescribed an entry inhibitor in combination with others as a backbone in 2014 was excluded

Back to article page